Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: New paradigms for the treatment of lysosomal storage diseases: targeting the endocannabinoid system as a therapeutic strategy

Fig. 1

Effect of FAAH inhibition in ASMD. All pathology in ASMD is initiated by sphingomyelin (SPM) build-up. FAAH inhibition leads to the elevation of AEA and other endocannabinoids (ECs), resulting in the activation of CB1. This, in turn, activates neutral sphingomyelinase (NSM), which slows or prevents SPM buildup and the resulting downstream pathology and disease

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172